source
- Capivasertib plus fulvestrant shows numerical overall-survival gain in PIK3CA/AKT1/PTEN-altered advanced breast cancerThe CAPItello-291 phase III trial enrolled 708 patients with advanced breast cancer and randomized them 1:1 to receive capivasertib (400 mg twice daily on a 4‑on/3‑off schedule) plus fulvestrant, o…
- Pimicotinib shows 76% response rate and functional benefits in TGCT phase 3 trialDr. Randall discussed results from the phase 3 MANEUVER trial of the CSF-1 receptor inhibitor pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The data were presented at the 2025…onclive · 4mo agoPositive readoutPositive